Skip to main content
Clinical Trials/NCT05044403
NCT05044403
Recruiting
Not Applicable

Clinical Impact of Hemoperfusion With a Neutral Macroporous Resin Cartridge as Adjunctive Treatment in Septic Patients With Multiorgan Dysfunction Syndrome (MODS) Admitted to Intensive Care Units.

Hospital Clinic of Barcelona1 site in 1 country48 target enrollmentMarch 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hemoperfusion
Sponsor
Hospital Clinic of Barcelona
Enrollment
48
Locations
1
Primary Endpoint
IL-6 plasmatic concentration
Status
Recruiting
Last Updated
10 months ago

Overview

Brief Summary

Low-level interventional clinical trial to evaluate the effectiveness and safety of extracorporeal support with hemoperfusion in critical patients with septic multiorgan dysfunction syndrome.

Registry
clinicaltrials.gov
Start Date
March 1, 2023
End Date
December 20, 2025
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with a sepsis diagnosis, according to the diagnostic criteria of the International Sepsis-3 Consensus Conference, and without response to the treatment of septic shock who meet the following conditions:
  • Sepsis of abdominal origin with controlled infectious focus.
  • Noradrenaline dose\> 0.5 µg / kg / min to maintain adequate organ perfusion after optimization of fluid therapy.
  • Dysfunction of two or more organs with SOFA ≥ 9 (5).
  • Blood lactate ≥ 2 mmol / L.
  • Procalcitonin (PCT)\> 10 ng / mL.
  • CRP\> 100 mg / L.
  • IL-6\> 2000 pg / ml.

Exclusion Criteria

  • Age under 18 years or over 80 years.
  • Pregnancy or breastfeeding.
  • Terminally ill patients or with a life expectancy of less than 48 hours.
  • Thrombocytopenia \<60,000 / mm
  • Pancytopenia.
  • Severe coagulopathy with high risk of bleeding.
  • Inclusion in another research protocol.
  • In case of re-entry during the study period, only the first admission will be included.
  • Use of another haemoperfusion device.

Outcomes

Primary Outcomes

IL-6 plasmatic concentration

Time Frame: During hemoperfusion

Analyze the patient's variation of IL-6 plasmatic concentration during the hemoperfusion process

Adverse events

Time Frame: During hemoperfusion

Analyze the presence of adverse events during the hemoperfusion process

Organ failure

Time Frame: During hemoperfusion

Analyze the number and severity of failed organs during the hemoperfusion process

Vasopressors dose

Time Frame: During ICU stay

Analyze the number of days on vasopressor support during ICU stay

Mean arterial pressure

Time Frame: During hemoperfusion

Analyze the patient's variation of mean arterial pressure during hemoperfusion

Mechanical ventilation

Time Frame: During ICU stay

Analyze the number of days on mechanical ventilation during ICU stay

Renal replacement therapy

Time Frame: During ICU stay

Analyze the number of days on renal replacement therapy during ICU stay

ICU length of stay

Time Frame: Post-Intensive Care Unit discharge

Analyze the patient's length of stay in ICU

ICU survival

Time Frame: Post-Intensive Care Unit discharge

Analyze the patient's survival in ICU

Hospital stay

Time Frame: post-hospital discharge

Analyze the patient's length of stay post-Intensive Care Unit discharge

Hospital survival

Time Frame: Post-hospital discharge

Analyze the patient's survival post-hospital discharge

Study Sites (1)

Loading locations...

Similar Trials